JUN 26, 2020 1:10 PM PDT

Combining Treatments to Improve Acute Myeloid Leukemia Therapy

WRITTEN BY: Jasper Cantrell

Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immature stem cells accumulate in the blood and interfere with healthy blood cells. AML, being a complex disease with many different sub-types, is notably a challenge to treat. Five-year survival rates are as low as 30%. 

One of the more common subtypes of AML is characterized by the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) mutation. Essentially there is an extra FLT3 gene where there shouldn’t be. FLT3 is a critical player in the differentiation of stem cells into mature cells, and too much of it in the cell can lead to runaway proliferation and cancer transformation.

FLT3 tyrosine kinase inhibitors (TKI) are a class of cancer drugs that specifically target FLT3. Gilteritinib is a new TKI with fewer side effects than other FLT3 TKIs, though it only has mild anti-cancer effects. Another FLT3-TKI, sorafenib, has had success in combination with the clinical drug arsenic trioxide (ATO).  A team from the School of Medicine at Shanghai Jiao Tong University in China hypothesized that combining gilteritinib with ATO could result in a synergistic similar anti-cancer effect.

Beginning with in vitro cell assays, they found that gilteritinib, in combination with ATO, worked better at reducing cell proliferation, invasion, and increasing cell death by apoptosis than either alone in FLT3-ITD cell lines. Further investigation showed that FLT3 was not the source of the synergy between the two drugs, but genes involved in endoplasmic reticulum stress were. One gene, IRE1a, has a role in a cell death pathway called apoptosis. Gilteritinib suppressed IRE1a expression, but cotreatment with ATO rescued IRE1a expression and induced cell death in cancer cells. The synergistic anti-cancer activity was confirmed in a mouse model, which showed combination therapy could reduce tumor growth better than either drug alone.

Other studies have similarly found that the addition of ATO to an FLT3-TKI could improve a treatment’s anti-cancer effects. Gilterinitib is a second-generation FLT3-TKI, with far fewer side effects seen from other FLT3-TKIs. The team found that combining gilteritinib with ATO, or possibly any drug that induced endoplasmic reticulum stress, could result in a far better therapy than either alone. The group concluded, “Our findings may provide a new target for combination treatment and a novel theoretical basis for the treatment of FLT3-ITD positive AML patients.”

Sources: Cancer Cell International, OncLiveTV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 04, 2020
Cancer
Commonly used pesticides, approved by EPA, linked to mammary gland tumors
AUG 04, 2020
Commonly used pesticides, approved by EPA, linked to mammary gland tumors
In an analysis of how regulators review pesticides for their potential to cause cancer, researchers at Silent Spring Ins ...
AUG 10, 2020
Cancer
A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer
AUG 10, 2020
A New Prognostic Biomarker for Paclitaxel Sensitivity in Breast Cancer
Breast cancer is one of the deadliest cancers globally. It has been studied extensively with plenty of treatments availa ...
AUG 11, 2020
Cancer
Aspirin could accelerate cancer progression in older adults
AUG 11, 2020
Aspirin could accelerate cancer progression in older adults
Alarming research published in the Journal of the National Cancer Institute points toward the association between a ...
SEP 07, 2020
Cancer
Identifying Robust Tumor Features for Better Radiomics
SEP 07, 2020
Identifying Robust Tumor Features for Better Radiomics
With the advancement of technology comes the renovation of classical medical techniques. Diagnostic is one of the areas ...
SEP 09, 2020
Cancer
Microbubbles enhance delivery of chemotherapy drug
SEP 09, 2020
Microbubbles enhance delivery of chemotherapy drug
New research published in APL Bioengineering reports on a new technology developed by scientists at Tulane Universi ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
Loading Comments...